drugset / Trial / NCT00861978

St. John's Wort Extract LI 160 for the Treatment of Atypical Depression

NCT00861978

Phase 3 Completed 201 enrolled Cassella-med GmbH & Co. KG
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.

Timeline

Start
2002-12
Primary completion
2004-11
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject St Johns Wort Extract Unknown 300 mg Oral